Condition: Ulcerative Colitis (UC) · Sponsor: University of Veterinary and Animal Sciences, Lahore - Pakistan
This randomized controlled trial aims to evaluate the effect of oral vitamin D3 supplementation on inflammatory biomarkers and disease activity in Pakistani patients with moderate ulcerative colitis. Sixty patients will be randomized to receive either standard treatment alone/Placebo or standard treatment plus vitamin D3 (50,000 IU fortnightly) for 12 weeks. Primary outcomes include changes in blood (CRP, ESR, IL-6) and fecal (calprotectin) inflammatory biomarkers, and disease activity assessed by the partial Mayo score. Secondary outcomes include vitamin D status, dietary intake, and quality of life. The study will provide insights into the immune-modulating and anti-inflammatory role of vitamin D3 as an adjunct therapy in ulcerative colitis.
This description comes directly from the study's public registry record.
Muhammad Barkaat Azam, PhD Scholar · 923336654554 · barkaatazam@gmail.com
Dr. Qaisar Raza, PhD · 923002479044 · qaisar.raza@uvas.edu.pk
Always discuss trial participation with your own doctor first.
| University of Veterinary & Animal Sciences, Lahore | Lahore, Punjab Province, Pakistan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07269223